Berchuck A - Search Results

1

Evidence of a genetic link between endometriosis and ovarian cancer.

Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL; Ovarian Cancer Association Consortium. Lee AW, et al. Among authors: berchuck a. Fertil Steril. 2016 Jan;105(1):35-43.e1-10. doi: 10.1016/j.fertnstert.2015.09.023. Epub 2015 Oct 23. Fertil Steril. 2016. PMID: 26477498 Free PMC article.

2

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

3

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

4

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

Schildkraut JM, Bastos E, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. doi: 10.1093/jnci/89.13.932. J Natl Cancer Inst. 1997. PMID: 9214672

5

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

6

Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ. Zweemer RP, et al. Among authors: berchuck a. J Clin Pathol. 1999 May;52(5):372-5. doi: 10.1136/jcp.52.5.372. J Clin Pathol. 1999. PMID: 10560359 Free PMC article.

7

Managing hereditary ovarian cancer risk.

Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Berchuck A, et al. Cancer. 1999 Dec 1;86(11 Suppl):2517-24. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2517::aid-cncr8>3.0.co;2-b. Cancer. 1999. PMID: 10630177 Review.

8

Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.

Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. Obstet Gynecol. 2000 Jan;95(1):119-27. doi: 10.1016/s0029-7844(99)00535-9. Obstet Gynecol. 2000. PMID: 10636514

9

An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.

Suzuki S, Moore DH 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. Suzuki S, et al. Among authors: berchuck a. Cancer Res. 2000 Oct 1;60(19):5382-5. Cancer Res. 2000. PMID: 11034075

10

Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Vine MF, et al. Among authors: berchuck a. Gynecol Oncol. 2001 Dec;83(3):466-71. doi: 10.1006/gyno.2001.6411. Gynecol Oncol. 2001. PMID: 11733956

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

632 results

Search Page